New pill targets Hard-to-Treat cancers driven by MYC genes
NCT ID NCT05546268
First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 29 times
Summary
This study tests an experimental oral drug, MRT-2359, in people with certain advanced cancers, including lung cancer and lymphoma, that are driven by MYC genes. The trial has two phases: first, finding a safe dose, and second, checking if the drug shrinks tumors. About 174 adults will take part across multiple centers.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Columbia University Irving Medical Centre
New York, New York, 10032, United States
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Fred Hutchinson Cancer Center
Seattle, Washington, 98109, United States
-
Henry Ford Cancer Institute
Detroit, Michigan, 48202, United States
-
Honor Health Research Institute
Scottsdale, Arizona, 85258, United States
-
MD Anderson Cancer Center
Houston, Texas, 77030-4009, United States
-
Mary Crowley Cancer Research
Dallas, Texas, 75251, United States
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10021, United States
-
Sarah Cannon Research Institute
Nashville, Tennessee, 37203, United States
-
South Texas Accelerated Research Therapeutics (START)
San Antonio, Texas, 78229, United States
-
South Texas Accelerated Research Therapeutics (START) Midwest
Grand Rapids, Michigan, 49546, United States
-
South Texas Accelerated Research Therapeutics (START) Mountain Region
West Valley City, Utah, 84119, United States
-
University of California San Diego
San Diego, California, 92037, United States
-
University of Kansas Cancer Center
Lawrence, Kansas, 66044, United States
-
Virginia Cancer Specialists Research Institute
Fairfax, Virginia, 22031, United States
-
Washington University
St Louis, Missouri, 63110, United States
-
Yale University
New Haven, Connecticut, 06520, United States
Conditions
Explore the condition pages connected to this study.